Group 1 - The core point of the article is that East China Pharmaceutical (SZ 000963) held its 11th fifth board meeting on November 20, 2025, to discuss the proposal for the second extraordinary shareholders' meeting of 2025 [1] - For the first half of 2025, East China Pharmaceutical's revenue composition is as follows: commercial brokerage and agency accounted for 68.23%, pharmaceutical manufacturing for 33.94%, medical beauty for 4.57%, and other businesses for 0.77%, with inter-segment eliminations at -7.5% [1] - As of the report date, East China Pharmaceutical has a market capitalization of 70.8 billion yuan [1]